Related references
Note: Only part of the references are listed.Dysregulated Lipid Metabolism Precedes Onset of Psychosis
Alex M. Dickens et al.
BIOLOGICAL PSYCHIATRY (2021)
Perinatal complications and executive dysfunction in early-onset schizophrenia
Charlotte M. Teigset et al.
BMC PSYCHIATRY (2020)
Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
Susan F. Sonnenschein et al.
FRONTIERS IN PSYCHIATRY (2020)
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality
Jeffrey A. Lieberman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Alteration in NMDAR-related amino acids in first episode psychosis
Beyazit Garip et al.
SYNAPSE (2019)
Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia
B. Galling et al.
ACTA PSYCHIATRICA SCANDINAVICA (2018)
Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
J. P. Kesby et al.
TRANSLATIONAL PSYCHIATRY (2018)
Current Concepts and Treatments of Schizophrenia
Piotr Stepnicki et al.
MOLECULES (2018)
A systematic review of metabolite biomarkers of schizophrenia
Jennifer Davison et al.
SCHIZOPHRENIA RESEARCH (2018)
Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients
Antonio Checa et al.
SCHIZOPHRENIA RESEARCH (2018)
Lipids in psychiatric disorders and preventive medicine
Miriam Schneider et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
David J. Hinton et al.
SCIENTIFIC REPORTS (2017)
Cigarette Smoking-Associated Alterations in Serotonin/Adrenalin Signaling Pathways of Platelets
Curtis Lee Lowery et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study
Dag K. Solberg et al.
BMC PSYCHIATRY (2016)
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
M. Gupta et al.
MOLECULAR PSYCHIATRY (2016)
Schizophrenia risk from complex variation of complement component 4
Aswin Sekar et al.
NATURE (2016)
Label-Free Proteomic Analysis of Protein Changes in the Striatum during Chronic Ethanol Use and Early Withdrawal
Jennifer R. Ayers-Ringler et al.
Frontiers in Behavioral Neuroscience (2016)
Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia
B. Dean et al.
TRANSLATIONAL PSYCHIATRY (2016)
Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia - significance for activation of the kynurenine pathway
Lilly Schwieler et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2015)
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia
Robin Emsley et al.
SCHIZOPHRENIA RESEARCH (2014)
Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation
Siham Raboune et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
Update on Typical and Atypical Antipsychotic Drugs
Herbert Y. Meltzer
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Potential metabolite markers of schizophrenia
J. Yang et al.
MOLECULAR PSYCHIATRY (2013)
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta-analysis
Wendela P. Hoen et al.
PSYCHIATRY RESEARCH (2013)
Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia
H. Y. Meltzer et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review
Maurizio Coppola et al.
NORDIC JOURNAL OF PSYCHIATRY (2012)
Mangiferin ameliorates 6-hydroxydopamine-induced cytotoxicity and oxidative stress in ketamine model of schizophrenia
Vietla S. Rao et al.
PHARMACOLOGICAL REPORTS (2012)
Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients
P. Bubber et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2011)
Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study
O. Howes et al.
MOLECULAR PSYCHIATRY (2011)
Integrated, Nontargeted Ultrahigh Performance Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry Platform for the Identification and Relative Quantification of the Small-Molecule Complement of Biological Systems
Anne M. Evans et al.
ANALYTICAL CHEMISTRY (2009)
Activation of brain interleukin-1β in schizophrenia
J. Soderlund et al.
MOLECULAR PSYCHIATRY (2009)
Stress-induced dopamine release in humans at risk of psychosis:: a [11C]raclopride PET study
Alexandra Soliman et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Metabolomic mapping of atypical antipsychotic effects in schizophrenia
R. Kaddurah-Daouk et al.
MOLECULAR PSYCHIATRY (2007)
CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis
Jeffrey T. -J. Huang et al.
PLOS ONE (2007)
Serotonin receptors : their key role in drugs to treat schizophrenia
HY Meltzer et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Share Paper
